An angiogenesis-related three-long non-coding ribonucleic acid signature predicts the immune landscape and prognosis in hepatocellular carcinoma.

The tumour microenvironment is a key determinant of the efficacy of immunotherapy. Angiogenesis is closely linked to tumour immunity. We aimed to screen long non-coding ribonucleic acids (lncRNAs) associated with angiogenesis to predict the prognosis of individuals with hepatocellular carcinoma (HCC) and characterise the tumour immune microenvironment (TIME). Patient data, including transcriptome and clinicopathological parameters, were retrieved from The Cancer Genome Atlas database. Moreover, co-expression algorithm was utilized to obtain angiogenesis-related lncRNAs. Additionally, survival-related lncRNAs were identified using Cox regression and the least absolute shrinkage and selection operator algorithm, which aided in constructing an angiogenesis-related lncRNA signature (ARLs). The ARLs was validated using Kaplan-Meier method, time-dependent receiver operating characteristic analyses, and Cox regression. Additionally, an independent external HCC dataset was used for further validation. Then, gene set enrichment analysis, immune landscape, and drug sensitivity analyses were implemented to explore the role of the ARLs. Finally, cluster analysis divided the entire HCC dataset into two clusters to distinguish different subtypes of TIME. This study provides insight into the involvement of angiogenesis-associated lncRNAs in predicting the TIME characteristics and prognosis for individuals with HCC. Furthermore, the developed ARLs and clusters can predict the prognosis and TIME characteristics in HCC, thereby aiding in selecting the appropriate therapeutic strategies involving immune checkpoint inhibitors and targeted drugs.